Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).
A scoring system, based on the immunophenotypic analysis of a panel of five membrane markers (CD5, CD22, CD23, FMC7, SmIg) was shown to be useful in the distinction between chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative diseases (non-CLL). We investigated whether the monoclonal antibody SN8 (CD79b) could improve our previous scoring system. Peripheral blood samples of 298 patients with CLL and 166 patients with non-CLL were analyzed by flow cytometry. Using the five standard markers, the accuracy of the scoring system was 91.8%, using a cutoff of 4 points or higher, to distinguish CLL from non-CLL. This was increased to 96.6% if SN8 was added and a cutoff of 4 points or higher was also used. A similar accuracy, 96.8%, was observed if CD22 was excluded and a cutoff of 3 points or higher was used. Thus, the replacement of CD22 by SN8 in the original scoring system significantly increases its potential to discriminate between CLL and other B-cell lymphoproliferative diseases.
Moreau
E J
EJ
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, England.
Matutes
E
E
A'Hern
R P
RP
Morilla
A M
AM
Morilla
R M
RM
Owusu-Ankomah
K A
KA
Seon
B K
BK
Catovsky
D
D
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D051925:CD79 Antigens; D003937:Diagnosis, Differential; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D015448:Leukemia, B-Cell / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D051925:CD79 Antigens; C497883:CD79B protein, human